NCT06151210View on ClinicalTrials.gov

Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis

PHASE3CompletedINTERVENTIONAL

Enrollment

467

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

July 10, 2025

Study Completion Date

July 15, 2025

Conditions

Gastritis AcuteGastritis Chronic

Interventions

DRUG

DA-5219

1 tablet/day

DRUG

Stillen® Tab

3 tablets/day

DRUG

DA-5219 Placebo

1 tablet/day

DRUG

Stillen® Tab Placebo

3 tablets/day

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT06151210 - Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis | Biotech Hunter | Biotech Hunter